Expression of HER2 in colorectal cancer does not correlate with prognosis

Disease Markers

Volumn 29, Issue 5, 2010, Pages 207-212

  Kruszewski, Wiesław Janusz ^a,b   Rzepko, Robert ^a   Ciesielski, MacIej ^a,b   Szefel, Jarosław ^b   Zieliński, Jacek ^a   Szajewski, Mariusz ^a,b   Jasiński, Wojciech ^b   Kawecki, Krzysztof ^b   Wojtacki, Janusz ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b PCK's Maritime Hospital in Gdynia   (Poland)

Author keywords

colorectal cancer; HER2; prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER CELL; CARCINOMA CELL; CELL MEMBRANE; CELL SURVIVAL; COLORECTAL CANCER; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STAINING;

EID: 79951526934     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.3233/DMA-2010-0742     Document Type: Article

References (24)

1. J. Baselga and S.M. Swain, Novel anticancer target: revisiting ERBB2 and discovering ERBB3, Nature Rev Cancer 9(2009), 463-475.
2. S. Essapen, H. Thomas, M. Green, C. De Vries, M.G. Cook, C. Marks, C. Topham and H. Modjtahedi, The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters, Int J Oncol 24 (2004), 241-248.
3. J. Ferlay, P. Autier, M. Boniol, M. Heanue, M. Colombet and P. Boyle, Estimates of the cancer incidence and mortality in Europe in 2006, Ann Oncol 18 (2007), 581-592. (Pubitemid 46359643)
4. C. Gravalos and A. Jimeno, HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target, Ann Oncol 19 (2008), 1523-1529.
5. E. Half, R. Broaddus, K.D. Danenberg, P.V. Danenberg, G.D. Ayers and F.A. Sinicrope, HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors, Int J Cancer 108 (2004), 540-548. (Pubitemid 38036654)
6. M. Harris, Monoclonal antibodies as therapeutic agents for cancer, Lancet Oncol 5 (2004), 292-302. (Pubitemid 38541581)
7. M. Hofmann, O. Stoss, D. Shi, R. Büttner, M. van de Vijver, W. Kim, A. Ochiai, J. Rüschoff and T. Henkel, Assessment of HER2 scoring system for gastric cancer: results from a validation study, Histopathology 52 (2008),797-805. (Pubitemid 351724903)
8. A.C. Hsieh and M.M. Moasser, Targeting HER proteins in cancer therapy and the role of the non-target HER3, Br J Cancer 97 (2007), 453-457. (Pubitemid 47258458)
9. D.O. Kavanagh, G. Chambers, L. O'Grady, K.M. Barry, R.P. Waldron, F.Bennani, P.W.Eustace and I. Tobbia, BMC Cancer 9 (2009), doi:10.1186/1471- 2407-9-1.
10. T. Knösel, Y. Yu, U. Stein, H. Shwabe, K. Schlüns, P.M. Schlag, M. Dietel and I. Petersen, Overexpression of c-erbB2 protein correlates with chromosomal gain at the c-erbB2 locus and patient survival in advanced colorectal carcinomas, Clin Exp Metastasis 19 (2002), 401-407. (Pubitemid 34879132)
11. H.K.W. Koeppen, B.D. Wright, A.D. Burt, P. Quirke, A.M. McNicol, N.O. Dybdal, M.X. Sliwkowski and K.J. Hillan, Overexpression of HER2/neu in solid tumours: an immuno-histochemical survey, Histopathology 38 (2001), 96-104. (Pubitemid 32194449)
12. P. Kountourakis, K. Pavlakis, A. Psyrri, D. Rontogianni, N. Xiros, E. Patsouris, D. Pectasides and T. Economopoulos, Clinicopathologic significance of EGFR and Her-2/neu in col-orectal adenocarcinomas, Cancer J 12 (2006), 229-236. (Pubitemid 43894340)
13. M. Mann, H. Sheng, J. Shao, C.S. Williams, P.I. Pisacane, M.X. Sliwkowski and R.N. DuBois, Targeting cyclooxyge-nase 2 and HER-2/neu pathway inhibits colorectal carcinoma growth, Gastroenterology 120 (2001), 1713-1719. (Pubitemid 32523489)
14. J. Matsubara, Y. Yamada, Y. Hirashima, D. Takahari, N.T. Okita, K. Kato, T. Hamaguchi, K. Shirao, Y. Shimada and T. Shimoda, Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer, Clin Cancer Res 14 (2008), 3022-3029.
15. M.M. Moasser, The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis, Oncogene 26 (2007), 6469-6487. (Pubitemid 47530601)
16. D.R. Nathanson, A.T. Culliford, J. Shia, B. Chen, M. D'Alessio, Z.-S. Zeng, G.M. Nash, W. Gerald, F. Barany and P.B. Paty, HER 2/neu expression and gene amplification in colon cancer, Int J Cancer 105 (2003), 796-802. (Pubitemid 36706103)
17. A. Ooi, T. Takehana, X. Li, S. Suzuki, K. Kunitomo, H. Iino, H. Fujii, Y. Takeda andY. Dobashi, Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study, Mod Pathol 17 (2004), 895-904. (Pubitemid 38993773)
18. T. Osako, M. Miyahara, S. Uchino, M. Inomata, S. Kitano and M. Kobayashi, Immunohistochemical study of c-erbB-2 protein in colorectal cancer and correlation with patient survival, Oncology 55 (1998), 548-55. (Pubitemid 28479114)
19. R.K. Ramanathan, J.J. Hwang, W.C. Zamboni, F.A. Sinicrope, H. Safran, M.K. Wong, M. Earle, A. Brufsky, T. Evans, M. Troetschel, C. Walko, R. Day, H.X. Chen and S. Finkelstein, Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase IItrial, Cancer Invest 22(2004), 858-865. (Pubitemid 39665350)
20. H.A. Rossi, Q. Liu, B. Banner, C.C. Hsieh, L. Savas and D. Savarese, The prognostic value of invariant chain (Ii) and HER-2/neu expressionincuratively resected colorectal cancer, Cancer J 8 (2002), 268-275.
21. D. Vernimmen, M. Gueders, S. Pisvin, P. Delvenne and R. Winkler, Different mechanisms are implicated in ERBB2gene overexpression in breast and in other cancers, Br J Surg 89 (2003), 899-906. (Pubitemid 37175814)
22. A.D. Wagner and U. Wedding, Advances in the pharmacological treatment of gastro-oesophageal cancer, Drugs Aging 26 (2009), 627-646.
23. A.C. Wolff, M.E.H. Hammond, J.N. Schwarz, K.L. Hagerty, D.C. Allred, R.J. Cote, M. Dowsett, P.L. Fitzgibbons, W.M. Hanna, A.Langer, L.M. McShane, S.Paik, M.D. Pegram, E.A. Perez, M.F. Press, A. Rhodes, C. Sturgeon, S.E. Taube, R. Tubbs, G.H. Vance, M. Vijver, T.M. Wheeler and D.F. Hayes, American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for human epidermal growth factor receptor 2 testing in breast cancer, Arch Pathol Lab Med 131 (2007), 18-43. (Pubitemid 46174133)
24. I. Zlobec, L. Terracciano, J.R. Jass and A. Lugli, Value of staining intensity in the interpretation of immunohistochem-istry for tumor markers in colorectal cancer, Virchows Arch 451 (2007), 763-769. (Pubitemid 47497938)